Since Folling's discovery of "imbecillitas phenylpyruvica" in 1934, knowledge of the nature of phenylketonuria (PKU) has broadened. In untreated patients, an accumulation of phenylalanine and its metabolites results in toxic damage of central nervous system due to an impairment of phenylalanine hydroxylase (PAH) activity. Through early diagnosis with neonatal screening, PKU might be eff ectively treated by a lowphenylalanine diet and/or tetrahydrobiopterin (sapropterin dihydrochloride, BH4) supplementation for PAH 
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Mozrzymas, R., Duś-Żuchowska, M., Kałużny, Ł., Wenska-Chyży, E., Walkowiak, J. (2016) . Phenylketonuria is not a risk factor for changes of infl ammation status as assessed by interleukin 6 and interleukin 8 concentrations. Acta Sci. Pol. Technol. Aliment., 15(2), 221-225. DOI: 10.17306/J. AFS.2016.2.22 cofactor responders. The risk for neurocognitive or psychological symptoms in PKU is related to age-ofonset of therapy, lifelong phenylalanine levels, and adherence to treatment (Blau et al., 2010; Folling, 1934; Groselj et al., 2014; Vockley et al., 2014) . The literature on early and continuously-treated PKU states that intelligence in patients with optimally treated PKU is comparable to the average population (Moyle et al., 2007; Vockley et al., 2014) .
As treatments for the disease become more eff ective, the children with phenylketonuria age producing a growing population of adults with absent or only mild forms of neurological defects who are then at risk of developing the potential problems specifi c to the adulthood such as ischemic heart disease, diabetes or cancer. The common denominators linking most of those latter diseases, also known as "Diseases of Civilization" are high oxidative stress (OS) and the infl ammatory process (Gonda et al., 2009; Reuter et al., 2010) .
Interleukin 6 (IL-6) and interleukin 8 (IL-8) are well known markers of infl ammation. IL-6 is a multifunctional cytokine that plays a role in such areas as the immune response, infl ammation, and hematopoiesis. IL-6 exerts pro-infl ammatory eff ects both locally and systemically, which increase the risk of diseases associated with infl ammation such as atherosclerosis and coronary heart disease. IL-6 stimulates liver production of acute phase proteins, activates endothelial cells, has pro-coagulant activity, and promotes proliferation and diff erentiation of lymphocytes (Hartman and Frishman, 2014; Heinrich et al., 1990; Hirano, 2014) . IL-8 was the fi rst described angiogenic chemokine. It is considered to be a strong chemokine that promotes angiogenesis, including the creation of new blood vessels in tumor growths (Koch et al., 1992; Rosenkilde and Schwartz, 2004) . Both IL-6 and IL-8 play a crucial role in the pathogenesis of sepsis in neonates. They are also known activators of nuclear factor κB (NF-κB) (Spasojević et al., 2012) . Proven involvement of the aforementioned substances in the infl ammatory process makes them good markers of infl ammation in the body.
The aim of the project is to evaluate the concentrations of interleukin 6 and 8 in the population of patients with PKU and to compare it with the control group.
MATERIAL AND METHODS
Study design 20 subjects (11 females and 9 males) aged 18-34 years (median value -24.5 years) with classical PKU from the Department of Pediatric Gastroenterology and Metabolic Diseases, Medical University, Poznań and the Voivodeship Hospital, Wrocław, Poland were enrolled in the study. Inclusion criteria were defi ned as: the diagnosis of classical PKU and an age greater than 10 years. Exclusion criteria were: non-classical forms of PKU (mild PKU, maternal PKU, mild hyperphenylalaninemia, BH4 defi ciency) and pregnancy. The control group comprised of 20 healthy subjects matched for age and sex.
Body mass and body height were measured and body mass index (BMI) was calculated in all study patients. Patient compliance status was checked by the last phenylalanine (Phe) level using fl uorometric method before study entry. The results are expressed as milligram per deciliter [mg/dL]. A venous blood sample (0.5 ml to clot) was collected according to standard methods following an overnight fast. In all study participants, interleukin 6 and 8 levels were measured by enzyme-linked immunosorbent assay (ELISA) kits (eBioscience, Vienna, Austria). The results are reported as picogram per milliliter [pg/mL].
Statistical analysis
Results are presented as means ± standard deviations (SD) and medians with interquartile ranges. The statistical signifi cance of diff erences in pro-infl ammatory cytokines' levels between patients and controls was determined with the use of Mann-Whitney U test. Rank-sum correlations of Phe blood levels with IL-6 or IL-8 were calculated (Spearman's ρ). General linear regression models were built, which included age, sex, BMI, Phe concentration, in order to identify risk factors for increased IL-6 and IL-8 concentrations. The signifi cance level was set at p < 0.05. Statistical analysis was carried out with STATISTICA 12 software packages (StatSoft Inc., Tulsa, USA). Informed, written consent was obtained from every participant of the study. The study protocol was accepted by the local Bioethics Committee of the Institutional Review Board at Poznan University of Medical Sciences, Poland (approval number 862/14).
Mozrzymas, R., Duś-Żuchowska, M., Kałużny, Ł., Wenska-Chyży, E., Walkowiak, J. (2016) 
RESULTS
A description of the anthropological parameters is given in Table 1 . IL-6 concentrations in the study group ranged from 0.74 pg/ml to 1.34 pg/ml. No significant diff erences were found in the IL-6 concentration between the study group and the control group (p = 0.989). IL-8 concentrations ranged from 17.56 pg/ml to 20.87 pg/ml. IL-8 levels didn't diff er signifi cantly between the study group and control group (p = 0.192; Table 2 ).
No signifi cant correlation was observed between Phe blood levels and IL-6 or IL-8 concentrations in the study group (ρ respectively: -0.225; 0.177). In a multivariate analysis, no relations between IL-6 nor IL-8 concentrations and sex, age, BMI and Phe levels were found.
DISCUSSION
The available data suggest a correlation between the infl ammatory process and OS. The recruitment of infl ammatory cells such as leukocytes and mastocytes during the infl ammatory process increases release and accumulation of reactive oxygen species (ROS). ROS modulate various transcription factors including NF-κB and activator protein-1 (AP-1), which regulate the gene-expression of many pro-infl ammatory mediators such as cytokines. As a consequence, a sustained infl ammatory or oxidative environment leads to a vicious circle (Coussens and Werb, 2002; Reuter et al., 2010) .
OS and infl ammation are involved in a wide spectrum of diseases; prime examples of which are neurodegenerative diseases (Uttara et al., 2009 ), cardiovascular disease (Holvoet, 2008) , atherosclerosis (Hartman and Frishman, 2014) and cancer (Gonda et al., 2009; Reuter et al., 2010) . The linkage between OS and infl ammation in neurodegenerative diseases makes the two an interesting target in the population of PKU patients.
A high OS status and a reduced potential of free radical scavenging in PKU patients has been confi rmed in a few studies (Rocha and Martins, 2012; Vargas et al., 2011) . Sanayama et al. demonstrated that OS status is closely linked with serum phenylalanine levels in PKU patients (Sanayama et al., 2011) . Shulpis et al observed that the antioxidant status was lower in patients noncompliant with dietary recommendations (Schulpis et al., 2003) .
To the best knowledge of the authors, there was only one study focused on the infl ammatory status in PKU patients (Deon et al., 2015) . It was focused on a group of patients diagnosed late in the course of the disease. Our study is the fi rst to assess the concentrations of interleukin 6 and 8 in the population of patients with PKU which was diagnosed by neonatal screening.
It is interesting that in our study we observed no signifi cant diff erences in IL-6 and IL-8 levels between the study and control group. Deon et al observed high lipid and protein oxidative damage, decreased antioxidant defenses, and an increased infl ammatory status (IL-6 and IL-1β) in PKU patients (Deon et al., 2015) . The discrepancy between Deon's and our results may result from diff erent characteristics of study group. Deon et al investigated patients diagnosed late with elevated Phe levels at study entrance. In our study, patients were detected by neonatal screening and checked again at study entrance, all the patients were under dietary treatment, and their Phe concentrations were lower than in the aforementioned study. Furthermore, two other limitations of Deon's study group was that it was smaller (n = 7 vs n = 20) and the time of effective dietary treatment was shorter. It seems Deon's results should be interpreted carefully.
Our fi ndings are in agreement with previous studies in which we assessed infl ammatory status of intestinal mucosa detected by fecal calprotectin. No correlation between Phe blood levels and fecal calprotectin concentrations was found in PKU patients (Walkowiak et al., 2013) .
CONCLUSIONS
Phenylketonuria is not a risk factor for changes of infl ammation status assessed by IL-6 and IL-8 concentrations.
